Case Studies
Trinity completed an engagement to support the successful launch of a CAR-T cell therapy with distinct clinical profile in a competitive landscape.
Geographic Scope:
Client Situation
The client asked Trinity to develop and externally validate global payer value messages and the associated evidence set for their CAR T cell therapy. They also required support with developing a robust global pricing and market access strategy for their asset.
Trinity’s Solution
Trinity conducted focus groups and In-Depth-Interviews (IDIs) with key payer and provider stakeholders in scope markets to understand…
Read Now
Case Studies
Trinity designed staggered quantitative research to assess the impact of national guidelines on uptake of a biomarker among HCPs and payers.
Geographic Scope:
Client Situation
The client wanted to understand the impact of national physician society guidelines on uptake / acceptance of an innovative biomarker based on developed patient vignettes, and expectations for updates to payer diagnostic testing polices.
Trinity’s Solution
Trinity conducted qualitative research, fielding a survey with physicians and payers, to determine current physician utilization and payer coverage of biomarker diagnostic test and track evolution in payer policies and…
Read Now
Case Studies
Trinity provided early P&MA forecasting support for a pipeline asset in development for several inflammatory conditions via secondary research.
Geographic Scope:
Client Situation
The client wanted to uncover the optimal launch strategy for their pipeline asset by understanding the current and future landscape across several inflammatory diseases to support indication prioritization.
Trinity’s Solution
Trinity conducted secondary research into the clinical treatment algorithms and current pricing and market access (P&MA) landscape of 19 inflammatory diseases to understand the unmet need, level of competition, payer management, contracting…
Read Now
Blog
Published August 19, 2021
Executive Summary
While 7 additional rare disease drugs were included on the 2020 NRDL in China, this development comes amid a backdrop of rare disease policy development signaling a move towards multi-channel funding mechanism to support more widespread patient access and maintain sustainability of the NRDL
As such, manufacturers cannot solely rely on NRDL inclusion for their rare disease product market access strategy in China and should consider alternative funding opportunities outside of the NRDL (e.g., provincial critical illness budgets,…
Read Now
Blog
Published August 16, 2021
Executive Summary
Recent updates in the National Drug Reimbursement List (NRDL) have increasingly focused on the expansion of oncology products and highlighted the improving market access environment for innovative oncology therapies in China
This effort first came under the spotlight in 2018 as the National Health Security Administration (NHSA) announced the inclusion of 17 novel oncology agents on the NRDL with discounts averaging ~60%. Subsequent NRDL updates saw comparable levels of price discounts and selection of products targeting the most…
Read Now
Webinars
Available On Demand
The HEOR Evidence Generation team at Trinity Life Sciences will conduct a webinar to discuss recent publications geared towards crafting the value story for products prior to launch. Please join us to learn what evidence is needed and how best to position it for successful commercialization. We will present original work conducted on behalf of our valued clients in several different therapeutic areas – Oncology, Cardiology, and Rare Genetic Disorders.You already know the importance of driving awareness and conducting market…
Watch Now
Webinars
Available On Demand
Among recent hot topics in pharma & biotech, few have been more prevalent than Agile methodologies–but what does “Agile” mean for pharma versus other industries? What are the critical Agile considerations unique to pharma, and what ad/promo, commercial operations, and compliance factors must be taken into consideration when setting up projects or pilots?
During this webinar, TGaS Advisors, a division of Trinity Life Sciences, explores what commercial pharma leaders need to know when considering implementation of Agile methodologies. Driven by…
Watch Now
Blog
Published August 2, 2021
Executive Summary:
A CMS regulation from the Trump Administration requiring hospitals to post lists containing the list price, negotiated private payer prices, and self-pay rates for up to 300 shoppable services took effect in January 2021 but is still widely ignored by hospitals
A lack of enforcement coupled with minor penalties decreases the efficacy of the requirement, resulting in low incentive for hospitals to comply with the rule
The data posted by compliant hospitals shows large variation in pricing for…
Read Now
Briefs
The elimination of third-party cookies is not a new concept. Safari and FireFox eliminated them a few years back. However, now the largest used browser (Chrome) is joining FireFox and Safari, announcing the imminent removal of third-party cookies in 2022. Organizations are attempting to navigate the impact and identify alternatives. Driven by increased user privacy, Google’s decision will require fundamental changes across media and advertising platforms.
The departure of third-party cookies will change the way pharmaceutical companies, in fact all…
Read Now
White Papers
Despite the challenges the COVID-19 pandemic created, 2020 was an exceptional year for the biopharma industry. The race to develop effective treatments and vaccines for COVID elevated the public’s perception of biotechnology, and, for many, the industry provided a source of hope during the pandemic. As early-stage venture capitalist Bruce Booth observed in his review of 2020, investors’ enthusiasm sent biotech indexes to all-time highs, boosted the performance of IPOs and accelerated venture capital funding. The NASDAQ Biotech Index finished…
Read Now
